Monorail
Hope, Rerouted
Exvade is driving a paradigm shift in oncology
For the first time, scientists and physicians can access tumor tissue on demand during treatment, unlocking real-time insights that accelerate drug development and redefine how cancer is treated.
Ability to guide intracortical brain tumor cells to an extra cortical reservoir
Provide path for on demand tissue access
Deliver treatment directly to site
Exvade, the opposite of ‘invade’, is focused on precision tumor removal
True to its name, Exvade turns cancer’s most dangerous trait into an opportunity for better care. Using bio-inspired cues, our device reroutes the invasive nature of malignant tumors into a safe, controlled pathway.
For the first time, migrating tumor cells can be guided to a small, accessible reservoir where they can be safely removed and analyzed to guide real-time, proactive treatment decisions.
Exvade provides
Real-time access to living tumor tissue in an outpatient setting, overcoming the risks and limitations of traditional biopsies.
Sufficient tumor material for deep insights, including multi-omics analysis to guide precision treatment.
A direct path through the blood-brain barrier, enabling targeted drug delivery once thought impossible.
Enroll in the trial
Exvade is conducting a First-in-Human study of the Tumor Monorail Device at the Preston Robert Tisch Brain Tumor Center at Duke University, evaluating its safety and advancing a transformative shift in how cancer is treated.
Enroll in our clinical trial and contribute to the development of innovative solutions that prioritize patient care and outcomes.
“By allowing real-time monitoring of the tumor over time, while on therapy, we will hopefully be able to more swiftly identify the degree of efficacy or the limitations of our therapies, while preventing the trauma and costs of repeated brain surgery.”
- Dr. Annick Desjardins, MD, FRCPC, neuro-oncologist,
professor of neurosurgery and neurology at Duke University
News
Join the future of cancer treatment
Exvade provides a credible, game-changing opportunity. Backed by high-impact publications, an extensive patent portfolio, and strategic partnerships, we’re building the future of cancer care.
Please feel free to contact us if you are a:
Patient/Caregiver looking for more information on our clinical trial
Biotech company focused on developing a new drug for GBM and would like to partner
Large pharma company running a Phase 1 or 2 clinical study and would like to partner to have access to tissue during your trials
